6-Feb-2026
FDA Clearance for Next-Gen Tablo Hemodialysis Marks Major Milestone for Outset Medical
Market Chameleon (Tue, 27-Jan 4:33 AM ET)
Next-Generation Tablo Hemodialysis System Receives FDA Clearance, Second Quarter Launch Planned
Globe Newswire (Tue, 27-Jan 9:00 AM ET)
Outset Medical to Report Fourth Quarter 2025 Financial Results on Wednesday, February 11, 2026
Globe Newswire (Mon, 26-Jan 4:05 PM ET)
Outset Medical Grows Revenue 5% and Lowers Cash Burn as Tablo Expands to Over 1,000 Sites
Market Chameleon (Mon, 12-Jan 4:54 AM ET)
Outset Medical's 2025 Revenue Grows 5% Amidst Operational Efficiencies and Board Refresh
Market Chameleon (Mon, 12-Jan 4:12 AM ET)
Outset Medical Reports Unaudited Fourth Quarter and 2025 Results
Globe Newswire (Mon, 12-Jan 8:30 AM ET)
PRNewswire (Thu, 8-Jan 10:00 AM ET)
Outset Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference
Globe Newswire (Mon, 5-Jan 4:05 PM ET)
PRNewswire (Thu, 1-Jan 10:00 AM ET)
Outset Medical Inc is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Company generates revenue from the sales of Tablo consoles and related consumables, including Tablo cartridges and accessories.
Outset Medical trades on the NASDAQ stock market under the symbol OM.
As of February 6, 2026, OM stock price climbed to $4.50 with 215,862 million shares trading.
OM has a beta of 1.96, meaning it tends to be more sensitive to market movements. OM has a correlation of 0.07 to the broad based SPY ETF.
OM has a market cap of $81.69 million. This is considered a Micro Cap stock.
Last quarter Outset Medical reported $29 million in Revenue and -$.69 earnings per share. This fell short of revenue expectation by $-1 million and exceeded earnings estimates by $.08.
In the last 3 years, OM traded as high as $448.65 and as low as $3.10.
The top ETF exchange traded funds that OM belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.
OM has underperformed the market in the last year with a price return of -62.5% while the SPY ETF gained +15.1%. OM has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -61.9% and -11.9%, respectively, while the SPY returned +3.3% and +0.2%, respectively.
OM support price is $4.06 and resistance is $4.72 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OM shares will trade within this expected range on the day.